The reported statements, read against the company's own industry.
Financials view
Market Capitalization
579.21BKRW
432.31M · vs all stocks (USD)
Updated Nov 20, 2026
Revenue (TTM)
22.78BKRW
17.00M · vs all stocks (USD)
Updated Nov 20, 2026
Profit Margin
-23.26%
vs Biotechnology peers
Updated Nov 20, 2026
Beta
0.7890x
vs all stocks
Updated Nov 20, 2026
52-Week Change
-19.83%
vs all stocks
Updated Nov 20, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Nov 20, 2026
Market Capitalization
579.21BKRW
432.31M · vs all stocks (USD)
Updated Nov 20, 2026
Enterprise Value
523.31BKRW
390.59M · vs all stocks (USD)
Updated Nov 20, 2026
Price to Sales (TTM)
24.69x
vs Biotechnology peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 25.43×.Updated Nov 20, 2026
Price to Book (MRQ)
5.29x
vs Biotechnology peers
Updated Nov 20, 2026
Enterprise to Revenue
22.97x
vs Biotechnology peers
Updated Nov 20, 2026
Enterprise to EBITDA
-41.04x
vs Biotechnology peers
Updated Nov 20, 2026
Gross Margin
42.98%
vs Biotechnology peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 25.2%.Updated Nov 20, 2026
Profit Margin
-23.26%
vs Biotechnology peers
Updated Nov 20, 2026
Operating Margin
-76.25%
vs Biotechnology peers
Updated Nov 20, 2026
Return on Assets (TTM)
-8.26%
vs Biotechnology peers
Updated Nov 20, 2026
Return on Equity (TTM)
-7.44%
vs Biotechnology peers
Updated Nov 20, 2026
Revenue (TTM)
22.78BKRW
17.00M · vs all stocks (USD)
Updated Nov 20, 2026
Revenue per Share (TTM)
710.42KRWUpdated Nov 20, 2026
Quarterly Revenue Growth
64.40%
vs Biotechnology peers
Updated Nov 20, 2026
Gross Profit (TTM)
5.74BKRW
4.28M · vs all stocks (USD)
Updated Nov 20, 2026
EBITDA (TTM)
-12.75BKRW
-9.52M · vs all stocks (USD)
Updated Nov 20, 2026
Net Income (TTM)
-5.30BKRW
-3.95M · vs all stocks (USD)
Updated Nov 20, 2026
Quarterly Earnings Growth (YoY)
64.43%
vs Biotechnology peers
Updated Nov 20, 2026
Operating Cash Flow (TTM)
-17.64BKRW
-13.16M · vs all stocks (USD)
Updated Nov 20, 2026
Levered Free Cash Flow (TTM)
-60.69BKRW
-45.29M · vs all stocks (USD)
Updated Nov 20, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Nov 20, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Nov 20, 2026
Revenue
19.32BKRWFY2025 · Dec 31, 2025
Cost of Goods Sold
15.67BKRWFY2025 · Dec 31, 2025
Gross Profit
3.65BKRWFY2025 · Dec 31, 2025
Operating Income
-12.19BKRW
-9.10M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-16.45BKRWFY2025 · Dec 31, 2025
Net Income
-16.45BKRWFY2025 · Dec 31, 2025
EBIT
-14.31BKRWFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-8.74BKRWFY2025 · Dec 31, 2025
Research & Development
28.38MKRWFY2025 · Dec 31, 2025
Selling, General & Administrative
5.54BKRWFY2025 · Dec 31, 2025
Other Operating Expenses
-194.20MKRWFY2025 · Dec 31, 2025
Non-operating Interest Income
449.95MKRWFY2025 · Dec 31, 2025
Non-operating Interest Expense
2.14BKRWFY2025 · Dec 31, 2025
EPS (Basic)
-601.00KRWFY2025 · Dec 31, 2025
EPS (Diluted)
-601.00KRWFY2025 · Dec 31, 2025
Basic Shares Outstanding
27.36MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
27.36MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-16.45BKRWFY2025 · Dec 31, 2025
Operating Cash Flow
-15.90BKRWFY2025 · Dec 31, 2025
Free Cash Flow
-58.52BKRWFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
40.43BKRWFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-16.45BKRWFY2025 · Dec 31, 2025
Stock-based Compensation
1.46BKRWFY2025 · Dec 31, 2025
Other Non-cash Items
1.44BKRWFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
177.55MKRWFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-2.53BKRWFY2025 · Dec 31, 2025
Capital Expenditures
-42.62BKRWFY2025 · Dec 31, 2025
Net Intangibles (CF)
-34.26MKRWFY2025 · Dec 31, 2025
Sale of Investments
9.46BKRWFY2025 · Dec 31, 2025
Other Investing Activity
-187.66MKRWFY2025 · Dec 31, 2025
Net Investing Cash Flow
-33.35BKRWFY2025 · Dec 31, 2025
Long-term Debt Issuance
39.43BKRWFY2025 · Dec 31, 2025
Long-term Debt Payments
-11.69BKRWFY2025 · Dec 31, 2025
Net Short-term Debt Issuance
-2.38BKRWFY2025 · Dec 31, 2025
Other Financing Charges
12.06MKRWFY2025 · Dec 31, 2025
Net Financing Cash Flow
67.37BKRWFY2025 · Dec 31, 2025
Shares Outstanding
34.50MSharesUpdated Nov 20, 2026
Float Shares
23.72MSharesUpdated Nov 20, 2026
% Held by Insiders
27.07%
vs all stocks
Updated Nov 20, 2026
% Held by Institutions
2.64%
vs all stocks
Updated Nov 20, 2026
Total Cash (MRQ)
72.23BKRW
53.91M · vs all stocks (USD)
Updated Nov 20, 2026
Total Cash per Share (MRQ)
2.08KKRWUpdated Nov 20, 2026
Total Debt (MRQ)
63.59BKRW
47.46M · vs all stocks (USD)
Updated Nov 20, 2026
Total Debt to Equity (MRQ)
0.6144x
vs Biotechnology peers
Updated Nov 20, 2026
Current Ratio (MRQ)
1.55x
vs Biotechnology peers
Updated Nov 20, 2026
Book Value per Share (MRQ)
2.99KKRWUpdated Nov 20, 2026
Total Assets
123.04BKRW
91.83M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
54.99BKRWFY2025 · Dec 31, 2025
Total Liabilities
54.44BKRWFY2025 · Dec 31, 2025
Total Non-current Assets
68.04BKRWFY2025 · Dec 31, 2025
Total Non-current Liabilities
6.37BKRWFY2025 · Dec 31, 2025
Total Current Liabilities
48.08BKRWFY2025 · Dec 31, 2025
Cash
287.00KKRWFY2025 · Dec 31, 2025
Cash Equivalents
40.43BKRWFY2025 · Dec 31, 2025
Cash & Cash Equivalents
40.43BKRWFY2025 · Dec 31, 2025
Accounts Receivable
2.47BKRWFY2025 · Dec 31, 2025
Inventory
4.85BKRWFY2025 · Dec 31, 2025
Accounts Payable
1.57BKRWFY2025 · Dec 31, 2025
Short-term Debt
38.04BKRWFY2025 · Dec 31, 2025
Other Current Liabilities
1.00KKRWFY2025 · Dec 31, 2025
Long-term Debt
5.27BKRWFY2025 · Dec 31, 2025
Other Non-current Liabilities
120.00KRWFY2025 · Dec 31, 2025
Common Stock (Book)
15.98BKRWFY2025 · Dec 31, 2025
Retained Earnings
-102.57BKRWFY2025 · Dec 31, 2025
Total Shareholders' Equity
68.59BKRW
51.20M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
13.86KKRWUpdated Nov 20, 2026
52-Week High
49.90KKRWUpdated Nov 20, 2026
52-Week Change
-19.83%
vs all stocks
Updated Nov 20, 2026
Beta
0.7890x
vs all stocks
Updated Nov 20, 2026
50-Day MA
24.77KKRWUpdated Nov 20, 2026
200-Day MA
33.66KKRWUpdated Nov 20, 2026
Avg 10-Day Volume
155.87KSharesUpdated Nov 20, 2026
Avg 30-Day Volume
178.04KSharesUpdated Nov 20, 2026
Diluted EPS (TTM)
-601.00KRWUpdated Nov 20, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.43Profit Margin: -0.23
Financial Health
Altman Z-Score 5.06: safe zoneNotable
Altman Z-Score: 5.06
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $17M, lower than 95% of all stocks globallySignificant